0.65
0.65 (0%)
As of Apr 17, 2025
Vor Biopharma Inc. [VOR]
Source:
Company Overview
Vor Bio is a clinical-stage company harnessing the power of cell and genome engineering to develop potentially transformative therapies in acute myeloid leukemia (“AML”), a devastating disease with few treatment options. AML is the most common type of acute leukemia in adults and one of the deadliest and most aggressive blood cancers, affecting approximately 20,000 newly diagnosed patients each year in the United States.
| Country | United States |
| Headquarters | cambridge, massachusetts |
| Phone Number | (617) 655-6580 |
| Industry | manufacturing |
| CEO | Robert Ang, M.B.B.S., M.B.A. |
| Website | www.vorbio.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-121.2 |
| Net Income | $-116.9 |
| Net Cash | $50.6 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -68.6% |
| Profit as % of Stockholder Equity | -121% |
Management Effectiveness
| Return on Equity | -121% |
| Return on Assets | -81.8% |
| Turnover Ratio | |
| EBITA | $-121.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $142.9 |
| Total Liabilities | $46.2 |
| Operating Cash Flow | $-99.7 |
| Investing Cash Flow | $96.9 |
| Financing Cash Flow | $53.4 |
